Thursday, May 11, 2006
Genentech Announces Vice President Appointments In Commercial Operations And Product Development
South San Francisco, Calif. -- May 11, 2006 -- Genentech, Inc. (NYSE: DNA) today announced two vice president appointments: Michael P. Miller to vice president, Sales and Marketing,HER Family*; and David Schenkein, M.D., to vice president, Clinical Hematology/Oncology.
Michael P. Miller
Vice President,Sales and Marketing,HER Family
Mike Miller, 49, joins Genentech as vice president, Sales and Marketing, HER Family, replacing John Orwin who was promoted to vice president, BioOncology; Miller will report to Orwin. In this role, Miller will be responsible for leading all sales and marketing activities for Herceptin® (Trastuzumab) and Tarceva® (erlotinib).
Miller joins Genentech from Connetics Corporation, where he was Senior Vice President, Chief Commercial Officer and led the commercial activities for the company's medical dermatology businesses.
Miller has over 25 years of pharmaceutical sales and marketing experience and has held various commercial leadership roles with Alza Corporation, Vivus Corporation and Syntex Laboratories.
Miller holds a Bachelor of Science in business administration from the University of San Francisco, and Master of Business Administration from San Francisco State University.
Vice President,Clinical Hematology/Oncology
David Schenkein, 49, joins Genentech as vice president, Clinical Hematology/Oncology, reporting to Hal Barron,M.D., senior vice president, Development, and chief medical officer. In this role, Schenkein will be responsible for leading the medical and scientific strategies for the Development BioOncology portfolio,as well as overseeing the BioOncology Clinical Science and Medical Science Liaison functions. Genentech's BioOncology marketed products include Avastin® (bevacizumab),Herceptin® (Trastuzumab), Rituxan® (Rituximab), and Tarceva® (erlotinib).
Schenkein joins Genentech from Millennium Pharmaceuticals, where he held several executive leadership positions,including most recently, Senior Vice President of Clinical Research. Prior to his positions at Millennium, Schenkein spent 18 years in academic/clinical medicine. Schenkein holds an attending physician appointment in Hematology Oncology at the Tufts-New England Medical Center in Boston, and previously held the position of Director of the Cancer Center. Additionally, Schenkein is an Associate Professor of Medicine at Tufts University School of Medicine.
Schenkein holds a Bachelor of Arts in Chemistry from Wesleyan University and a medical degree from the State University of New York Upstate Medical School.
Founded 30 years ago, Genentech is a leading biotechnology company that discovers,develops,manufactures,and commercializes biotherapeutics for significant unmet medical needs. A considerable number of the currently approved biotechnology products originated from or are based on Genentech science. Genentech manufactures and commercializes multiple biotechnology products and licenses several additional products to other companies. The company has headquarters in South San Francisco, Calif., and is listed on the New York Stock Exchange under the symbol DNA. For additional information about the company, please visit http://www.gene.com.
* The HER Family includes the oncology products Herceptin and Tarceva.